Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Semin Arthritis Rheum. 2011 Apr 1;41(2):194–202. doi: 10.1016/j.semarthrit.2011.02.005

Table 4.

Change in ANAM throughput scores at 12 weeks for patients that were at least 1 standard deviation below normal control data on at least one of the 9 ANAM subtests or one of the 21 ACR Neuropsychiatric battery at baseline

Neuropsychiatric Measure Memantine Placebo P Valuea
n=24 n=13
ANAM throughput score:
Code substitution, delayed memory 0.4 ± 15.0 4.7 ± 9.8 0.36
Code substitution, immediate memory 6.8 ± 15.7 7.0 ± 9.5 0.97
Code substitution 7.7 ± 7.6 7.0 ± 8.9 0.78
Continuous performance test 14.5 ± 13.5 3.2 ± 29.8 0.21
Matching to sample 1.2 ± 6.1 2.5 ± 4.9 0.51
Mathematical processing 3.6 ± 7.6 1.7 ± 3.0 0.31
Simultaneous spatial processing 5.0 ± 6.3 4.0 ± 3.6 0.55
Simple reaction time 23.2 ± 36.9 −0.3 ± 48.1 0.11
Sternberg memory recall 6.3 ± 13.5 5.9 ± 11.4 0.92
ACR neuropsychiatric battery: n=26 n=16
 Minimental State Exam 0.2 ± 1.4 0.5 ± 1.1 0.41
 Woodcock total −0.2 ± 2.9 0.0 ± 3.2 0.81
 Trails A −3.5 ± 11.3 −5.6 ± 15.0 0.62
 Trails B −6.8 ± 27.0 −15.5 ± 26.6 0.32
 Rey total - copy 0.1 ± 4.0 1.7 ± 7.9 0.45
 Rey total – immediate recall 6.5 ± 4.2 4.9 ± 6.3 0.41
 Rey total – delayed recall 5.9 ± 5.7 6.7 ± 9.0 0.76
 Symbol score 2.7 ± 7.7 1.9 ± 10.0 0.76
 California Delay LDFR 2.7 ± 0.6 1.5 ± 3.8 0.24
 California Delay LDCR 3.0 ± 2.5 1.6 ± 2.6 0.09
 California Delay – Hits 0.7 ± 1.8 0.4 ± 2.5 0.68
 California Delay – FP −0.8 ± 2.0 0.1 ± 1.7 0.13
 Block total 2.8 ± 7.7 6.8 ± 6.0 0.09
 COWAT - F 2.2 ± 4.7 2.4 ± 4.6 0.85
 COWAT - A 0.2 ± 4.2 1.6 ± 3.1 0.29
 COWAT – S 3.1 ± 4.5 0.6 ± 3.9 0.08
 Coding score 4.5 ± 18.4 −3.9 ± 20.1 0.17
 Tap dominant 6.7 ± 9.4 2.7 ± 7.7 0.16
 Tap nondominant 6.3 ± 10.2 2.0 ± 10.6 0.16
 Digit forward 0.6 ± 2.1 0.9 ± 2.0 0.64
 Digit backward 1.0 ± 1.9 −0.1 ± 2.4 0.11
a

From two-sample t-test.